Reduction in tumour cell invasion by pigment epithelium-derived factor is mediated by membrane type-1 matrix metalloproteinase downregulation

Pharmazie

Volumn 67, Issue 12, 2012, Pages 1010-1014

  Filiz, G ^a   Dass, Crispin R ^a  

^a VICTORIA UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTEGRIN; COLLAGEN TYPE 1; FOCAL ADHESION KINASE; MATRIX METALLOPROTEINASE 14; PIGMENT EPITHELIUM DERIVED FACTOR; PROTEIN CDC42; RAC1 PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL ADHESION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; COLLAGEN TYPE I; DOWN-REGULATION; EYE PROTEINS; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 14; NEOPLASM INVASIVENESS; NERVE GROWTH FACTORS; PROSTATIC NEOPLASMS; SERPINS;

EID: 84870334887     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2012.2067     Document Type: Article

References (40)

1. Abe R, Shimizu T, Yamagishi S, Shibaki A, Amano S, Inagaki Y, Watanabe H, Sugawara H, Nakamura H, Takeuchi M, Imaizumi T, Shimizu H (2004) Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am J Pathol 164: 1225-1232. (Pubitemid 38387789)
2. Akiyama T, Dass CR, Shinoda Y, Kawano H, Tanaka S, Choong PF (2010) PEDF regulates osteoclasts via osteoprotegerin and RANKL. Biochem Biophys Res Commun 391: 789-794.
3. American Cancer Society (2011) Cancer Facts and Figures. Atlanta: American Cancer Society.
4. Anderson BO (2006) Breast healthcare and cancer control in limited-resource countries: a framework for change. Nat Clin Pract Oncol 3: 4-5.
5. Broadhead ML, Becerra SP, Choong PF, Dass CR (2010) The applied biochemistry of PEDF and implications for tissue homeostasis. Growth Factors 28: 280-285.
6. Broadhead ML, Choong PF, Dass CR (2012) Systemically administered PEDF peptides show efficacy against primary and secondary osteosarcoma. J Biotech Biomed, in press.
7. Broadhead ML, Dass CR, Choong PF (2011) Systemically administered PEDF against primary and secondary tumours in a clinically relevant osteosarcoma model. Br J Cancer 105: 1503-1511.
8. Bruera E, Sweeney C (2003) Bone pain. In Bruera, E., Portenoy, R. K. (eds) Cancer pain assessment and management, Cambridge University Press, Cambridge.
9. Cai J, Parr C, Watkins G, Wang JS, Xu HT, Zhang GQ, Pang D (2006) Decreased pigment epithelium-derived factor expression in human breast cancer progression. Clin Cancer Res 12: 3510-3517.
10. Charles AG, Han TY, Liu YY, Hansen N, Giuliano AE, Cabot MC (2001) Taxol-induced ceramide generation and apoptosis in human breast cancer cells. Cancer Chemother Pharmacol 47: 444-450. (Pubitemid 32397622)
11. Chernov AV, Sounni NE, Remacle AG, Strongin AY (2009) Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2axis in cancer cells. J Biol Chem 284: 12727-12734.
12. Crawford SE, Stellmach V, Ranalli M, Huang X, Huang L, Volpert O, De Vries GH, Abramson LP, Bouck N (2001) Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. J Cell Sci 114: 4421-4428. (Pubitemid 34082862)
13. Dass CR, Choong PF (2008) uPAR mediates anticancer activity of PEDF. Cancer Biol Ther 7: 1262-1270.
14. Dass CR, Ek ET, Contreras KG, Choong PF (2006) A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma. Clin Exp Metastasis 23: 367-380. (Pubitemid 46197119)
15. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285: 245-248. (Pubitemid 29329995)
16. Doll JA, Stellmach VM, Bouck NP, Bergh AR, Lee C, Abramson LP, Cornwell ML, Pins MR, Borensztajn J, Crawford SE (2003) Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med 9: 774-780. (Pubitemid 36749229)
17. Ek ET, Dass CR, Contreras KG, Choong PF (2007a) Inhibition of orthotopic osteosarcoma growth and metastasis by multitargeted antitumor activities of pigment epithelium-derived factor. Clin Exp Metastasis 24: 93-106. (Pubitemid 46669247)
18. Ek ET, Dass CR, Contreras KG, Choong PF (2007b) Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis. Cancer Gene Ther 14: 616-626. (Pubitemid 46912035)
19. Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM (2003) Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med 9: 1026-1032. (Pubitemid 37021782)
20. Filleur S, Volz K, Nelius T, Mirochnik Y, Huang H, Zaichuk TA, Aymerich MS, Becerra SP, Yap R, Veliceasa D, Shroff EH, Volpert OV (2005) Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer. Cancer Res 65: 5144-5152. (Pubitemid 40827323)
21. Guan M, Jiang H, Xu C, Xu R, Chen Z, Lu Y (2007) Adenovirus-mediated PEDF expression inhibits prostate cancer cell growth and results in augmented expression of PAI-2. Cancer Biol Ther. 6: 419-425. (Pubitemid 47328311)
22. Halin S, Wikström P, Rudolfsson SH, Stattin P, Doll JA, Crawford SE, Bergh A (2004) Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors. Cancer Res 64: 5664-5671. (Pubitemid 39095563)
23. Konson A, Pradeep S, Seger R (2010) Phosphomimetic mutants of pigment epithelium-derived factor with enhanced antiangiogenic activity as potent anticancer agents. Cancer Res 70: 6247-6257.
24. Manalo K, Choong PF, Dass CR (2011) Pigment epithelium-derived factor as an impending therapeutic agent against vascular epithelial growth factor-driven tumor-angiogenesis. Mol Carcino 50: 62-72.
25. Nishibaba R, Higashi Y, Su J, Furukawa T, Kawai K, Kanekura T (2012) CD147-targeting siRNA inhibits cell-matrix adhesion of human malignant melanoma cells by phosphorylating focal adhesion kinase. J Dermatol 39: 63-67.
26. Notari L, Miller A, Martínez A, Amaral J, Ju M, Robinson G, Smith LE, Becerra SP (2005) Pigment epithelium-derived factor is a substrate for matrix metalloproteinase type 2 and type 9: implications for downregulation in hypoxia. Invest Ophthalmol Vis Sci 46: 2736-2747. (Pubitemid 43086693)
27. Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4: 448-456. (Pubitemid 38745530)
28. Parkin DM, Fernández LM (2006) Use of statistics to assess the global burden of breast cancer. Breast J 12: S70-80. (Pubitemid 43385274)
29. Pillay V, Dass CR, Choong PF (2007) The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol 25: 33-39. (Pubitemid 46001467)
30. Qingyi Z, Lin Y, Junhong W, Jian S, Weizhou H, Long M, Zeyu S, Xiaojian G (2009) Unfavorable prognostic value of human PEDF decreased in high-grade prostatic intraepithelial neoplasia: a differential proteomics approach. Cancer Invest 27: 794-801.
31. Sidle DM, Maddalozzo J, Meier JD, Cornwell M, Stellmach V, Crawford SE (2005) Altered pigment epithelium-derived factor and vascular endothelial growth factor levels in lymphangioma pathogenesis and clinical recurrence. Arch Otolaryngol Head Neck Surg 131: 990-995. (Pubitemid 41696394)
32. Smith ND, Schulze-Hoepfner FT, Veliceasa D, Filleur S, Shareef S, Huang L, Huang XM, Volpert OV (2008) Pigment epithelium-derived factor and interleukin-6 control prostate neuroendocrine differentiation via feed-forward mechanism. J Urol 179: 2427-2434.
33. Ta HT, Dass CR, Larson I, Choong PF, Dunstan DE (2009) A chitosan-dipotassium orthophosphate hydrogel for the delivery of Doxorubicin in the treatment of osteosarcoma. Biomaterials 30: 3605-3613.
34. Tan ML, Dass CR, Choong PF (2010) Anti-chondrosarcoma effects of PEDF mediated via apoptosis, decreased cell cycling, increased adhesion and decreased invasion. Biochem Biophys Res Commun 398: 613-618.
35. Tan ML, Friedhuber AM, Dunstan DE, Choong PF, Dass CR (2010) The performance of doxorubicin encapsulated in chitosan-dextran sulphate microparticles in an osteosarcoma model. Biomaterials 31: 541-551.
36. Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, Amin M, Bouck NP (2002) Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 8: 349-357. (Pubitemid 34407029)
37. Weigelt B, Wessels LF, Bosma AJ, Glas AM, Nuyten DS, He YD, Dai H, Peterse JL, van't Veer LJ (2005) No common denominator for breast cancer lymph node metastasis. Br J Cancer 93: 924-932. (Pubitemid 41487019)
38. Yang J, Duh EJ, Caldwell RB, Behzadian A (2010) Anti-permeability function of PEDF involves blockade of MAP kinase/GSK/beta-catenin signaling pathway and uPAR expression. Invest Ophthalmol Vis Sci 51: 3273-3278.
39. Yu HG, Tong SL, Ding YM, Ding J, Fang XM, Zhang XF, Liu ZJ, Zhou YH, Liu QS, Luo HS, Yu JP (2006) Enhanced expression of cholecystokinin-2 receptor promotes the progression of colon cancer through activation of focal adhesion kinase. Int J Cancer 119: 2724-2732. (Pubitemid 44846222)
40. Zhou D, Cheng SQ, Ji HF Wang JS, Xu HT, Zhang GQ, Pang D (2010) Evaluation of protein pigment epithelium-derived factor (PEDF) and microvessel density (MVD) as prognostic indicators in breast cancer. J Cancer Res Clin Oncol 136: 1719-1727.